Up a level |
Din, Shahida, Kent, Alexandra, Pollok, Richard C, Meade, Susanna, Kennedy, Nicholas A, Arnott, Ian, Beattie, R Mark, Chua, Felix, Cooney, Rachel, Dart, Robin J et al (show 24 more authors)
(2020)
Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel.
GUT, 69 (10).
pp. 1769-1777.
Kennedy, Nicholas A, Jones, Gareth-Rhys, Lamb, Christopher A, Appleby, Richard, Arnott, Ian, Beattie, R Mark, Bloom, Stuart, Brooks, Alenka J, Cooney, Rachel, Dart, Robin J et al (show 26 more authors)
(2020)
British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic.
GUT, 69 (6).
pp. 984-990.
Quraishi, Mohammed Nabil, Dobson, Elizabeth, Ainley, Rachel, Din, Shahida, Wakeman, Ruth, Cummings, Fraser, Sebastian, Shaji, Bloom, Stuart, Limdi, Jimmy K, Dhar, Anjan et al (show 6 more authors)
(2023)
Establishing key performance indicators for inflammatory bowel disease in the UK.
FRONTLINE GASTROENTEROLOGY, 14 (5).
pp. 407-414.
Lenti, Marco Vincenzo, Dolby, Vivien, Clark, Tanya, Hall, Veronica, Tattersall, Suzanne, Fairhurst, Francesca, Kenneth, Catherine, Walker, Rachael, Kemp, Karen, Borg-Bartolo, Simon et al (show 11 more authors)
(2022)
A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn's disease. The Cross Pennine study II.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 55 (7).
pp. 856-866.
Lenti, Marco Vincenzo, Levison, Scott, Eliadou, Elena, Willert, Robert, Kemp, Karen, Carter, Anna, Stansfield, Catherine, Assadsangabi, Arash, Singh, Salil, Crooks, Ben et al (show 13 more authors)
(2018)
A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study.
DIGESTIVE AND LIVER DISEASE, 50 (12).
pp. 1299-1304.